rian.ie - Results

A A A

Current Search:	'Cancer' in all fields;

Displaying Results 176 - 200 of 2032 on page 8 of 82

Mark

Lipid Raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. (2012)

Donatello, Simona; Babina, Irina S; Hazelwood, Lee D; Hill, Arnold DK; Nabi, Ivan R; Ho...

Mark

An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. (2011)

Donatello, Simona; Hudson, Lance; Cottell, David C; Blanco, Alfonso; Aurrekoetxea, Igor...

Mark

Development and validation of a clinical prediction rule to identify suspected breast cancer: a prospective cohort study (2014)

Galvin, Rose; Joyce, Doireann; Downey, Eithne; Boland, Fiona; Fahey, Tom; Hill, Arnold K

Mark

South Central Strategic Health Authority: Cancer inequalities (2007)

Oxford Cancer Intelligence Unit

Mark

Reply: cost-effectiveness of population-based screening for colorectal cancer. (2013)

Sharp, Linda; Walsh, Cathal Dominic; Whyte, Sophie; Tilson, Lesley; O'Ceileachair,...

Mark

Exercise in cancer care in Ireland: a survey of oncology nurses and physiotherapists (2014)

O'Hanlon, É.; Kennedy, N.

Mark

Cancer mortality in Ireland: 1976-1986. (1987)

Seymour, Colin; Herity, Bernadette; Moriarty, Michael J.

Mark

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. (2016)

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véro...

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véronique; Dahan, Laetitia; Glehen, Olivier; Vasseur, Frederique; Lacornerie, Thomas; Piessen, Guillaume; El Hajbi, Farid; Robb, William B; Clisant, Stéphanie; Kramar, Andrew; Mariette, Christophe; Adenis, Antoine

Abstract:

<p>The original article is available at www.biomedcentral.com</p>
<p>BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemo...